Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing migraine.
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
1372
|
Provisional Schedule
| Expected publication |
14 October 2020 |
Project Team
| Project lead |
Gemma Barnacle |
Email enquiries
| Evidence Review Group / Assessment Group |
Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Consultees
| Companies sponsors |
Eli Lilly (galcanezumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Migraine Trust |
| |
National Migraine Centre |
| Professional groups |
Association of British Neurologists |
| |
British Association for the Study of Headache |
| |
Royal College of Physicians |
| |
UK Clinical Pharmacy Association |
Commentators
| Comparator companies |
Accord (amitriptyline, propranolol, topiramate) (confidentiality agreement not signed, not participating) |
| |
Allergan (botulinum toxin type A) |
| |
Aurobindo Pharma-Milpharm (topiramate) (confidentiality agreement not signed, not participating) |
| |
Brown & Burk UK (amitriptyline) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals (topiramate) (confidentiality agreement not signed, not participating) |
| |
Janssen-Cilag (topiramate) |
| |
Novartis (erenumab) |
| |
Rosemont Pharmaceuticals (amitriptyline, propranolol, topiramate) (confidentiality agreement not signed, not participating) |
| |
Sandoz (propranolol) (confidentiality agreement not signed, not participating) |
| |
Teva (fremanezumab) |
| |
Thame Laboratories (amitriptyline, propranolol) (confidentiality agreement not signed, not participating) |
| |
Wockhardt (amitriptyline) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
22 November 2019
|
Invitation to participate |
|
22 November 2019
|
In progress, Referred 2 August 2019. |
|
10 September 2019
|
The Department for Health and Social Care has asked us to carry out a Single Technology Appraisal of galcanezumab for preventing migraine.
The appraisal is expected to start in approximately late November 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE until after the anticipated marketing authorisation has been received, in order to facilitate a suitably comprehensive and robust evidence submission. |
|
28 January 2019 - 25 February 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance